GLP-1 Ra proved to ameliorate GPT (standardized mean difference (SDM), −0.56, 95% CI −0.88 to −0.25, p < 0.01) and GOT (SDM, −0.44, SE, 95% CI −0.64 to −0.24, p < 0.01), and reduced the liver fat content (SDM, −0.43, 95% CI −0.74 to −0.12, p < 0.01) in patients with T2DM and nonalcoholic fatty liver disease (NAFLD). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.